Literature DB >> 21849805

Matrix metalloproteinase-13 promotes recovery from experimental liver cirrhosis in rats.

Hitoshi Endo1, Maki Niioka, Yoshihiko Sugioka, Johbu Itoh, Kaori Kameyama, Isao Okazaki, Risto Ala-Aho, Veli-Matti Kähäri, Tetsu Watanabe.   

Abstract

OBJECTIVE: To evaluate the role of matrix metalloproteinase (MMP)-13 gene expression in the early phase of recovery from liver fibrosis/cirrhosis.
METHODS: Liver fibrosis was induced in male Wistar rats by administration of carbon tetrachloride (CCl(4)) for 10 weeks. Recombinant adenovirus-mediated human MMP-13 gene transfer (RAdMMP-13) was performed via the femoral vein on day 3 after the last CCl(4) injection. The role of MMP-13 in stably expressing cell lines was also analyzed.
RESULTS: Fibrous deposition in the liver was decreased in RAdMMP-13-injected rats by day 3 after gene transfer compared with empty vector RAd66-injected rats. Furthermore, MMP-2 and MMP-9 enzymatic activity was markedly enhanced in the liver of RAdMMP-13 injected rats. Hepatocyte growth factor (HGF) induction was also increased in RAdMMP-13 injected rats. In established stable HT-1080 cells transfected with MMP-13, HGF-α expression and MMP-2 and MMP-9 enzymatic activity were increased. The conversion of precursor HGF into mature HGF was also increased in the MMP-13 expressing cell lines.
CONCLUSION: Forced MMP-13 expression effectively accelerated recovery from liver cirrhosis via the effects of MMP-13-mediated HGF, MMP-2, and MMP-9 expression, which induced the degradation of collagen fibers and promoted hepatic regeneration.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849805     DOI: 10.1159/000328841

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  28 in total

Review 1.  Resolution of organ fibrosis.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

2.  Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis.

Authors:  Theerut Luangmonkong; Su Suriguga; Emilia Bigaeva; Miriam Boersema; Dorenda Oosterhuis; Koert P de Jong; Detlef Schuppan; Henricus A M Mutsaers; Peter Olinga
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

Review 3.  Matrix Metalloproteinases (MMPs) in Liver Diseases.

Authors:  Adnan Naim; Qiuwei Pan; Mirza S Baig
Journal:  J Clin Exp Hepatol       Date:  2017-10-03

4.  Collagen Turnover in Wound Repair--A Macrophage Connection.

Authors:  Liisa M Nissinen; Veli-Matti Kähäri
Journal:  J Invest Dermatol       Date:  2015-10       Impact factor: 8.551

5.  Twist1 in Infiltrating Macrophages Attenuates Kidney Fibrosis via Matrix Metallopeptidase 13-Mediated Matrix Degradation.

Authors:  Jiafa Ren; Jiandong Zhang; Nathan P Rudemiller; Robert Griffiths; Yi Wen; Xiaohan Lu; Jamie R Privratsky; Michael D Gunn; Steven D Crowley
Journal:  J Am Soc Nephrol       Date:  2019-07-17       Impact factor: 10.121

Review 6.  Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar?

Authors:  Michele T Pritchard; Jennifer M McCracken
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 7.  Matrix metalloproteinases in liver injury, repair and fibrosis.

Authors:  Sergio Duarte; John Baber; Takehiro Fujii; Ana J Coito
Journal:  Matrix Biol       Date:  2015-01-16       Impact factor: 11.583

Review 8.  Diverse functions of matrix metalloproteinases during fibrosis.

Authors:  Matthew Giannandrea; William C Parks
Journal:  Dis Model Mech       Date:  2014-02       Impact factor: 5.758

9.  MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability.

Authors:  Mervi Toriseva; Matti Laato; Olli Carpén; Suvi T Ruohonen; Eriika Savontaus; Masaki Inada; Stephen M Krane; Veli-Matti Kähäri
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

10.  Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.

Authors:  Hitoshi Endo; Maki Niioka; Noriko Kobayashi; Mamoru Tanaka; Tetsu Watanabe
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.